Who Are You Taking Advice From?

The first year I started working out at a gym I saw no results on my body.  It took me a second year to gain muscle and start to lose body fat.  I couldn't afford to pay a personal trainer I had to learn on my own through trial and error.  I did get some help from a few gym members.  I decided to ask the bodybuilders to give me pointers.  I was very young so they were willing to help me out.

It is important to get the right advice from the right people.  If you go to a gym with 500 members all of which are men you will surely get advice from each one of them if you ask, even if they have no clue what they are doing.  I did not waste time asking those with no results how I should go about transforming my body.  It took a lot of time, patience and discipline to get what I wanted.

The same can be said about finance.  Who are you getting advice from?

If you hang out with smart people you will make smart choices.  If you hang out with positive people you will become a positive person.  If you hang out with wealthy people you will be wealthy yourself. Nobel Prize winners usually have students that end up receiving a Nobel Prize of their own.

Pretty simple whatever you want in life make sure you get the right type of advice.  You get what you pay for a low price most likely equals a poor answer and a poor outcome.  When the person you need is not available get their book.  While I got experience at the gym I read a lot about workout routines, human anatomy and nutrition.  I didn't know at the time that my interests would come in handy later on.  It all depends on how badly you want what you are looking for I am willing to travel to look for the information I need.  Next time you need help or feel stuck in life make sure to go get advice from a reliable and respectable source.

5 Mistakes Young Adults Make

1. Don't Save Enough
    Young adults seem to skip on the savings and go straight to the spending.  Having a good time is not bad but make sure you don't spend it all on things and people that won't matter a few years from now.




2. Don't Risk Enough
    Yes, playing it too safe will not pay off.  You have so much time ahead of you when you are young that even if you risk big and lose you will have plenty of time to gather yourself back up.  On the other hand what if the risk does pay off?




3. Comparing Yourself To Others
    We all know that there will always be people that are nicer, smarter, stronger etc  
What you don't always see is that you may be wrong some of the time.  Others may not be better off or immune to disrespect, illness and bad events.  Be happy for other people's success.




4. Not Enough Exercise
    School and work can take up a lot of our time so typically we rather have a good time with friends or family or just rest when we are done with those obligations.  Yet if we do commit and exercise our health will be at an optimal level making our old age less expensive and more enjoyable.  Once you become a senior and ill this will be the worst time to start exercising you will find it very hard.




5. Don't Volunteer
    It's not all about us we exist in a very connected world not only talking about humans here.  If you begin your life just worrying about yourself and self centered you will not be a very good family member, spouse, friend and mentor.  You will also feel empty and not satisfied even if you fulfill some or most of your goals.  You want to make a difference, help your community and fix some of the negatives you saw growing up.  This will bring satisfaction to your life and pick you up during the tough times.

Del Mar Pharmaceuticals Inc.

Del Mar (DMPI) a Canadian based Pharmaceutical company founded in 2010 with its main player VAL-083 which is currently in the clinical trial stage in the U.S. for refractory glioblastoma multiforme (GBM).  Glioblastomas are the most aggressive form of brain cancer so aggressive that even under high levels of radiation the tumors may show no sign of ever receiving radiation.  The small-molecule

chemotherapeutic is already approved in China for lung cancer and chronic myelogenous leukemia. 

The bar is set higher in the U.S. both clinically and regulatory. 

As an investor I stay away from most OTC securities as they come with high risk.  As a man of medicine obsessed with the brain and cancer the stock seems promising and may surprise investors with a blockbuster drug.  Yet I have traded for quite a while so I know best to look for fundamental or technical analysis.  According to SeeThruEquity a NYC independent equity research firm they had modeled that Del Mar would have raised $2mn in 2014 yet DMPI reported a working capital of $4.1mn said to last the biotech company well into the first quarter of 2015 in regards to R&D. SeeThruEquity has a $4.53 price target for the company.

It is typical that newly founded pharmaceutical companies operate on negative cash flow during the clinical trial process.

Del Mar could be uplisted to either the NYSE or NASDAQ.  Making it a good investment for the long run or until it gets FDA approval.  The FDA already gave VAL-083 Orphan Drug Status.  Temodar and Avastin are the current drugs on the market for GBM.  The drug is a last result treatment but if it is approved it could become a front line treatment.  The company will make updates in regards to VAL-083 at the American Association Cancer Research Annual Meeting (April 5-9) in San Diego, CA. 

The Board of Directors includes two MBAs, a Ph.D and a Doctor of Medicine who practices at Columbia-Presbyterian.  Del Mar has three Advisors who either practice Neurosurgery or Neurology.

The stock has stayed in the $1-$1.4 range (after hitting a high of $2.4 in May 2013) for almost a year typical of a OTC security.

Without treatment victims with GBM will only survive for 4-5 months.  With treatment (chemo, radiation & Temodar) the survival rate is about 15 months.

If approved VAL-083 may generate $100s of millions in North America and possibly billions worldwide.  On the other hand if the drug fails to receive approval that will most likely be the end of Del Mar and a monetary loss to investors.  

Glioblastoma Multiforme - this one has crossed the midline
to the opposite hemisphere.
Neoplasms are quite vascular.